Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

DECEMBER 27, 2019

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 112

Research and Development Data THC Clinical Trials 112

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. ABOUT ANANDA SCIENTIFIC.

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

Cannabis Law Report

JUNE 4, 2021

Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Phase 2 trial underway. Clinical trial information: NCT03276572 ( [link] ). Actinium-225 radiolabeled J591 safe at tested dosage.

Data 100

Data Research and Development Clinical Trials Therapy 100

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JULY 8, 2021

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. . – July 28, 2021) – PharmaDrug Inc.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Veriheal

FEBRUARY 9, 2023

Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Magic Mushrooms: The Ticket to a Stress-Free MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JULY 25, 2022

together with research collaborators at the University of Auckland , have received NZ$1.44 million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). mentalhealth #help #lsd #menta … [link].

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

SEPTEMBER 29, 2021

This trial is being led by principal investigators Edythe London, Ph.D., Funding for this trial is from the National Institute on Drug Abuse (NIDA). “We We are excited to be moving forward with this trial in conjunction with ANANDA ,” said Dr. De La Garza. GREENWOOD VILLAGE, Colo. & ABOUT ANANDA SCIENTIFIC.

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. Junk’ cannabis ‘ill-suited for clinical trials’.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

NOVEMBER 9, 2021

Pavel Otáhal, contributing author and Head of the Gene Immunotherapy Research Department at ÚHKT, stated, “Our study compares the manufacture of CAR19 T-cells via PCR-made transposon DNA (LinearDNA) with mRNA encoding of the transposase against a conventional plasmid approach. Dr. James A. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. For this reason, the compound was abandoned by its developer and never marketed.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

CannaTech

SEPTEMBER 23, 2019

This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Furthermore, pharmaceutical companies often fund and initiate randomised clinical trials to validate their drugs.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Food and Drug Administration (“FDA”). About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We This product candidate is being funded through a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS).

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 10, 2021

Shanti”), and all its assets focused on psychedelic MDMA-based drug development. This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

NOVEMBER 10, 2021

– Multiple Contracts Awarded to Support the Development and Manufacturing of Envelta (NES100) – BERWYN, Pa.–(BUSINESS IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (CRADA) with NCATS entered into by Virpax in August of 2020. “We

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

SEPTEMBER 14, 2021

The new Radicle Science-OBX alliance fills an unmet need for rigorous scientific research in the cannabis industry and sets a new gold standard for CBD and minor cannabinoid product development.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

NOVEMBER 15, 2021

a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, today announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization (CRO) order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

SpeedWeed

AUGUST 11, 2021

According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug development research, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Still, research is ongoing. Parkinson’s disease and cannabis. The effectiveness of cannabis for Parkinson’s disease.

Patients 89

Patients Clinical Trials Research and Development Treatment 89

Cannabis Law Report

JULY 28, 2021

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Support Regulatory Affairs in the planning, development, and publishing of submissions.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

SpeedWeed

SEPTEMBER 17, 2021

“Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Lately, MAPS research zeroed in on MDMA-assisted therapy for PTSD.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. For example, research shows that primary care physicians misdiagnosed 65.9% Building the Data Backend.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

AUGUST 17, 2021

This growth opportunity-technology report explores innovations and patents in this space and provides more details about notable companies that are making strides in research and development. Research Context and Key Findings. Research Scope. Research Methodology. Research Context and Key Findings.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98